Telix Pharmaceuticals Limited
55 Flemington Road
About Telix Pharmaceuticals Limited
A clinical-stage biotechnology company dedicated to the development and commercialisation of molecurlarly-targeted radiation (MTR) therapy.
12 articles with Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited announces it has submitted a New Drug Application to the United States Food and Drug Administration for TLX591-CDx, a radiopharmaceutical targeting Prostate-Specific Membrane Antigen for the imaging of prostate cancer using Positron Emission Tomography.1
Telix Pharmaceuticals Enters Strategic Collaboration with Varian Medical Systems for Advanced Prostate Imaging - Sep 03, 2020
Telix Pharmaceuticals Limited announced it has entered into a strategic collaboration agreement with Palo Alto-based Varian Medical Systems, to evaluate the use of advanced prostate cancer imaging within Varian’s radiation treatment planning platform.
ARTMS Announces New Appointments to Executive Leadership TeamCompany adds experienced executives to support the continued expansion of commercial activities and focus on radiopharmaceutical innovator and manufacturer relationships
ARTMS Inc., the global leader in the development and commercialization of technologies that are transforming the production of the world’s most-used diagnostic imaging isotopes, announced that it has expanded its senior management team with the addition of two industry veterans, Doug Gentilcore as Chief Commercial Officer and Mark Przekop as Vice President of Marketing and Business Development.
RefleXion and Telix Pharmaceuticals Announce Strategic Collaboration for Treatment of High-Risk Cancers
RefleXion Medical , a therapeutic oncology company pioneering biology-guided radiotherapy* ( BgRT ) as a new modality for treating all stages of cancer, and Telix Pharmaceuticals Limited (ASX: TLX), a radiopharmaceutical company developing molecularly-targeted radiation ( MTR ) products, today announced a strategic collaboration to investigate the clinical utility of combining the companies’
ARTMS Products Inc . (ARTMS), a global leader in the development of novel technologies enabling the production of the world’s highest demand diagnostic imaging isotopes, and Telix Pharmaceuticals Limited (Telix), a clinical-stage biopharmaceutical company developing diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR) announced today they have entered into a development
Heidelberg Pharma AG announced that it has received a milestone payment of 250 TUSD from its cooperation partner Telix Pharmaceuticals Limited, Melbourne, Australia,.
Telix Pharmaceuticals and Cardinal Health Enter into Distribution Agreement for Prostate Cancer Imaging
Telix Pharmaceuticals (US) Inc. today announced that it has entered into a distribution agreement with Cardinal Health (NYSE:CAH).
Heidelberg Pharma AG: Partner Telix Pharmaceuticals Files Phase III Trial for Kidney Cancer Imaging in Europe
Heidelberg Pharma AG (ISIN DE000A11QVV0 / WKN A11QVV / WL6) today announced that its partner Telix Pharmaceuticals Limited ("Telix") (ASX:TLX), has submitted a Clinical Trial Application (CTA) to initiate a Phase III trial in Europe for 89Zr-DFO-girentuximab (TLX250) for the imaging of renal (kidney) cancer with Positron Emission Tomography (PET).
Telix Pharmaceuticals Limited and Nihon Medi-Physics Co., Ltd. have today announced that they have entered into a memorandum of understanding (MOU) for a commercial partnership in renal cancer imaging for the Japanese market.
Telix Pharmaceuticals Limited is pleased to announce that Memorial Sloan Kettering Cancer Center (“MSK”) has imaged the first two patients in a 500 patient Phase II Expanded-Access Investigational New Drug (IND) study for imaging prostate cancer with the investigational agent 68Ga-PSMA-11
Telix Pharmaceuticals Limited has announced a technology transfer and manufacturing agreement with ISOLOGIC Innovative Radiopharmaceuticals
The purpose of the subsidiary is to support the Company’s Japanese clinical and radiopharmaceutical manufacturing activities and to establish a commercial footprint in the Japan, an important market for Telix’s products.